A nonfunctional neuroendocrine tumor of the pancreas - a case report

Vol. 56 No. 2 Suppl., 2015
This supplement was not sponsored by Outside Organizations.


Stelian Stefanita Mogoanta, Adrian Costache, Gabriela Mutiu, Simona Gabriela Bungau, Mirela Ghilusi, Florin Grosu, Manuela Vasile, Ionica Daniel Vilcea, Mircea Constantin Gherghinescu, Laurentiu Mogoanta, Daniela Adriana Ion

Pancreatic neuroendocrine tumors (pNETs) represent about 1-5% of the pancreatic tumors, having an annual incidence of about 1/100 000, with difficult positive and differential diagnostic, especially in nonfunctioning tumors. We present a case of large dimensions (10/8 cm) pancreatic tail NET developed in a 65-year-old woman, incidentally discovered while she was examined for a strangled inguinal hernia. The patient had no specific tumor signs and the imagistic examination did not reveal any metastases. The histopathological and especially the immunohistochemical examinations were decisive for the diagnosis, treatment and prognostic establishment. The tumor showed intense positivity for chromogranin, synaptophysin, CD56, CD117, CK19, MNF-116 and negative for CK5/6 and CK7. The proliferative index established through the Ki-67 assessment was around 3%, while p53 was positive in 25-30% of tumor cells nuclei.

Corresponding author: Adrian Costache, Associate Professor, MD, PhD; e-mail: adriancostacheeco@yahoo.com

Download PDF


Mariana Costache, Adrian Vasile Dumitru, Oana Maria Patrascu, Daniela Alina Popa-Cherecheanu, Patricia Badila, Jeni Catalina Miu, Alexandru Procop, Manuela Popa, Mircea-Stefan Tampa, Maria Sajin, Olga Simionescu, Monica Mihaela Cirstoiu

Ocular melanoma is a rare malignancy found in clinical practice. In this paper, we present a case of highly aggressive ocular melanoma, which was surgically removed at the Department of Ophthalmology and diagnosed at the Department of Pathology, Emergency University Hospital, Bucharest, Romania, using conventional histopathological techniques. Uveal melanoma, a subset of ocular melanoma, has a distinct behavior in comparison to cutaneous melanoma and has a widely divergent prognosis. Approximately half of patients with ocular melanoma will develop metastatic disease, predominantly with hepatic, pulmonary or cerebral location, over a 10 to 15 years period. No systemic therapy was associated with an evident clinical outcome for patients with advanced disease and overall survival rate remains poor.

Corresponding author: Adrian Vasile Dumitru, MD; e-mail: eldarlight@yahoo.com

Download PDF
Download cover
Download contents

Journal archive